JP2013532970A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532970A5 JP2013532970A5 JP2013515850A JP2013515850A JP2013532970A5 JP 2013532970 A5 JP2013532970 A5 JP 2013532970A5 JP 2013515850 A JP2013515850 A JP 2013515850A JP 2013515850 A JP2013515850 A JP 2013515850A JP 2013532970 A5 JP2013532970 A5 JP 2013532970A5
- Authority
- JP
- Japan
- Prior art keywords
- human insulin
- cysteine
- amino acid
- chain
- analogue according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 79
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 45
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 27
- 235000018417 cysteine Nutrition 0.000 claims 22
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 20
- 102200127556 rs34159654 Human genes 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 235000001014 amino acid Nutrition 0.000 claims 11
- 125000000539 amino acid group Chemical group 0.000 claims 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 10
- 102220030552 rs398124174 Human genes 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 230000015572 biosynthetic process Effects 0.000 claims 5
- 239000004026 insulin derivative Substances 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000004071 biological effect Effects 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 102000003746 Insulin Receptor Human genes 0.000 claims 2
- 108010001127 Insulin Receptor Proteins 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000000717 retained effect Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 206010061818 Disease progression Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000002608 insulinlike Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 238000002741 site-directed mutagenesis Methods 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10167036.2 | 2010-06-23 | ||
| EP10167036 | 2010-06-23 | ||
| US35912710P | 2010-06-28 | 2010-06-28 | |
| US61/359,127 | 2010-06-28 | ||
| PCT/EP2011/060295 WO2011161083A1 (en) | 2010-06-23 | 2011-06-21 | Human insulin containing additional disulfide bonds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532970A JP2013532970A (ja) | 2013-08-22 |
| JP2013532970A5 true JP2013532970A5 (enExample) | 2014-08-07 |
| JP6013330B2 JP6013330B2 (ja) | 2016-10-25 |
Family
ID=43242457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013515850A Expired - Fee Related JP6013330B2 (ja) | 2010-06-23 | 2011-06-21 | 追加のジスルフィド結合を含有するヒトインスリン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8883722B2 (enExample) |
| EP (1) | EP2585483A1 (enExample) |
| JP (1) | JP6013330B2 (enExample) |
| CN (1) | CN102933599A (enExample) |
| WO (1) | WO2011161083A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5931857B2 (ja) | 2010-06-23 | 2016-06-08 | ノヴォ ノルディスク アー/エス | 追加のジスルフィド結合を含有するインスリン誘導体 |
| US9187547B2 (en) * | 2011-03-15 | 2015-11-17 | Novo Nordisk A/S | Human insulin analogues and derivatives comprising cysteine substitutions |
| CN104364262A (zh) * | 2011-12-21 | 2015-02-18 | 诺沃—诺迪斯克有限公司 | N末端修饰的胰岛素衍生物 |
| GB2555639B (en) | 2016-11-07 | 2022-02-09 | Rheon Labs Ltd | Activity monitoring |
| CN111781288B (zh) * | 2020-07-23 | 2023-10-31 | 中国计量科学研究院 | 确定多肽二硫键位置的方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE50892B1 (en) | 1980-02-11 | 1986-08-06 | Novo Industri As | Process for preparing insulin esters |
| DK58285D0 (da) * | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
| DK105489D0 (da) | 1989-03-03 | 1989-03-03 | Novo Nordisk As | Polypeptid |
| DK155690D0 (da) * | 1990-06-28 | 1990-06-28 | Novo Nordisk As | Nye peptider |
| IL114160A (en) | 1994-06-17 | 2006-12-31 | Novo Nordisk As | Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast |
| JP4773023B2 (ja) | 1999-12-29 | 2011-09-14 | ノボ ノルディスク アクティーゼルスカブ | インスリン前駆体及びインスリン前駆体類似体の製造方法 |
| AU2003903124A0 (en) * | 2003-06-20 | 2003-07-10 | Mark Del Borgo | Analogues of heteromeric proteins |
| JP4463814B2 (ja) | 2003-08-05 | 2010-05-19 | ノボ ノルディスク アクティーゼルスカブ | 新規のインスリン誘導体 |
| WO2007135117A2 (en) * | 2006-05-24 | 2007-11-29 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations |
| BRPI0717098B8 (pt) * | 2006-09-22 | 2021-05-25 | Novo Nordisk As | análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação |
| MY152979A (en) * | 2008-01-09 | 2014-12-15 | Sanofi Aventis Deutschland | Novel insulin derivatives having an extremely delayed time-action profile |
| EP2254905B1 (en) | 2008-03-14 | 2016-12-14 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
| JP2012511506A (ja) | 2008-12-09 | 2012-05-24 | ノヴォ・ノルディスク・アー/エス | 新規インスリンアナログ |
| US20120184488A1 (en) | 2009-09-01 | 2012-07-19 | Case Western Reserve University | Insulin analogues of enhanced receptor-binding specificity |
-
2011
- 2011-06-21 WO PCT/EP2011/060295 patent/WO2011161083A1/en not_active Ceased
- 2011-06-21 JP JP2013515850A patent/JP6013330B2/ja not_active Expired - Fee Related
- 2011-06-21 EP EP11726432.5A patent/EP2585483A1/en not_active Withdrawn
- 2011-06-21 US US13/805,494 patent/US8883722B2/en not_active Expired - Fee Related
- 2011-06-21 CN CN2011800295163A patent/CN102933599A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013530702A5 (enExample) | ||
| JP2013530974A5 (enExample) | ||
| DK2727605T3 (en) | EXENDIN-4 ANALOG PEGYLED WITH POLYETHYLENE LYCOL OR A DERIVATIVE THEREOF, PROCEDURE FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DIABLE SUBSTANCES, | |
| KR102092025B1 (ko) | 페길화된 옥신토모둘린 변이체 | |
| JP2014129355A5 (enExample) | ||
| JP2014520798A5 (enExample) | ||
| US20170088598A1 (en) | Long-acting oxyntomodulin variants and methods of producing same | |
| JP2013532970A5 (enExample) | ||
| RU2012157683A (ru) | Производные инсулина, содержащие дополнительные дисульфидные связи | |
| JP2013515055A5 (enExample) | ||
| CN108463468B (zh) | 一种人胰岛素或其类似物的酰化衍生物 | |
| JP2014534265A5 (enExample) | ||
| PH12015500989A1 (en) | Long-acting single-chain insulin analogues | |
| JP2016516076A5 (enExample) | ||
| JP2014526441A5 (enExample) | ||
| WO2009043466A3 (en) | Therapeutic use of the peptide gluten exorphin a5 | |
| WO2009043463A3 (en) | Use of gluten exorphin c : as a therapeutic agent | |
| JP2013517307A5 (enExample) | ||
| JP2011526886A5 (enExample) | ||
| RU2013145013A (ru) | Новые аналоги глюкагона | |
| JP2017500289A5 (enExample) | ||
| TWI463991B (zh) | 生長抑素(somatostatin)或其類似物之持續釋放型藥學組成物 | |
| NZ600477A (en) | Insulin analogues with chlorinated amino acids | |
| WO2009033760A3 (en) | Use of fibronectin fragment (196-203 ) as a therapeutic agent | |
| JP2013518090A5 (enExample) |